Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 482-485, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chmielewska, J.
Right arrow Articles by Wiman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chmielewska, J.
Right arrow Articles by Wiman, B.

Clinical Chemistry, Vol 32, 482-485, Copyright © 1986 by American Association for Clinical Chemistry

Determination of tissue plasminogen activator and its "fast" inhibitor in plasma

J Chmielewska and B Wiman

We describe efficient, accurate methods for specific determination of tissue plasminogen activator (t-PA, EC 3.4.21.31) and its "fast" inhibitor in plasma. In this coupled assay, a sample containing t-PA is incubated with plasminogen, a plasmin (EC 3.4.21.7) substrate of low Km and high Kcat, and fibrin as a stimulator. The inhibitor of t-PA is determined by incubating the sample with a known amount of t-PA in excess, then determining the residual t-PA. Both t-PA and t-PA inhibitor can be determined in many samples simultaneously within a few hours. These assays are modifications of procedures described by us (Clin Chim Acta 1983;127:279-88 and Thromb Res 1983;31:427-36). Their accuracy as assessed by analytical recovery of pure t-PA added to blood samples (91 +/- 4%) or of partly purified inhibitor added to plasma samples (102 +/- 10%) is satisfactory, as is their precision. For the t- PA assay the CV was 1.6% (within run) or 4.1% (between run). The corresponding values for the inhibitor assay were 4.5% (within run) or 8.4% (between run) if the inhibitor concentration exceeded 3 arb. units/mL.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. Rej
Clinical Chemistry through Clinical Chemistry: A Journal Timeline
Clin. Chem., December 1, 2004; 50(12): 2415 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. M. Herrington, B. E. Pusser, W. A. Riley, T. Y. Thuren, K. B. Brosnihan, E. A. Brinton, and D. B. MacLean
Cardiovascular Effects of Droloxifene, a New Selective Estrogen Receptor Modulator, in Healthy Postmenopausal Women
Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1606 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
S. M Wileman, N. A Booth, N. Moore, B. Redmill, J. V Forrester, and R. M Knott
Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells
Br. J. Ophthalmol., April 1, 2000; 84(4): 417 - 422.
[Abstract] [Full Text]

Home page
 JAMAHome page
B. W. Walsh, L. H. Kuller, R. A. Wild, S. Paul, M. Farmer, J. B. Lawrence, A. S. Shah, and P. W. Anderson
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
JAMA, May 13, 1998; 279(18): 1445 - 1451.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. A. Ehrmann, D. J. Schneider, B. E. Sobel, M. K. Cavaghan, J. Imperial, R. L. Rosenfield, and K. S. Polonsky
Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2108 - 2116.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
C. Cimminiello, M. Milani, T. Uberti, G. Arpaia, A. Motta, and G. Bonfardeci
t-PA, PAI, and Protein C Before and After Vascular Occlusion of the Upper Limb in Patients with Raynaud's Phenomenon
Angiology, March 1, 1991; 42(3): 231 - 238.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.